# Jeff He

> Jeff He is the co-founder and CEO of TandemAI. Previously a co-founder and CFO of Harbour BioMed and a co-founder and COO of HiFiBiO Therapeutics, he combines experience in finance, strategy and operations with an engineering degree, an economics master’s and an Emory MBA. His earlier career included Intel, Bain & Company, Saint-Gobain, Danaher/Fluke, TPG and ShangPharma/ChemPartner.

- **Role:** Co-founder and CEO at TandemAI
- **Organizations:** TandemAI, HiFiBiO Therapeutics, Harbour BioMed, ShangPharma/ChemPartner, TPG, Danaher/Fluke, Saint-Gobain, Bain & Company, Intel
- **Education:** Bachelor’s degree in engineering, Zhejiang University, M.S. in Economics, Shanghai University of Science and Technology (as named in his published biography), MBA, Emory University, Goizueta Business School
- **Known for:** Co-founded Harbour BioMed, HiFiBiO Therapeutics and TandemAI., Helped privatize ShangPharma from the NYSE while at TPG., Led TandemAI through announced financing rounds of $25 million in 2021, $35 million in 2023 and $22 million in 2025.

## Career timeline

- **—** — Early career as a senior financial analyst at Intel and strategy consultant at Bain & Company.
- **—** — Management roles at Saint-Gobain and Danaher/Fluke, followed by a senior vice president role at TPG, helping privatize ShangPharma from the NYSE.
- **—** — Executive vice president of strategy and operations at ShangPharma/ChemPartner for three years.
- **2015-2017** — Co-founder and CFO of Harbour BioMed.
- **2017** — Became co-founder and COO of HiFiBiO Therapeutics.
- **2017** — Co-authored a paper with Liang Schweizer on structuring collaborative innovation.
- **2021** — Co-founded TandemAI; company founded in October and announced $25 million seed and pre-Series A financing in December.
- **2023** — TandemAI announced a $35 million Series A and released TandemViz 1.0.
- **2025** — Continued as CEO of the combined TandemAI following its announced merger with Perpetual Medicines; company announced a $22 million Series A extension in November.
- **2026** — TandemAI announced a research partnership with Mila in May.

## Achievements

- Co-founded Harbour BioMed, HiFiBiO Therapeutics and TandemAI.
- Helped privatize ShangPharma from the NYSE while at TPG.
- Led TandemAI through announced financing rounds of $25 million in 2021, $35 million in 2023 and $22 million in 2025.
- Led the combined TandemAI following the 2025 Perpetual Medicines merger.
- Co-authored a 2017 published framework for collaborative innovation with Liang Schweizer.

## Latest updates

- **2026-06** — Perpetual Medicines, which merged with TandemAI, and Third Rock Ventures announced a project milestone that triggered a milestone payment.
- **2026-05** — TandemAI and Mila announced a research partnership exploring world models and chemical and atomic-level physical systems.
- **2025-11** — TandemAI announced a $22 million Series A extension to support model development and laboratory capacity expansion.
- **2025-07** — TandemAI announced its merger with Perpetual Medicines; Jeff He would lead the combined company.

## Links

- LinkedIn: https://www.linkedin.com/in/jeff-he-268486/

---

Profile page: https://yespress.io/jeff-he
Published by YesPress — https://yespress.io
Last updated: 2026-10-26